Evidence map›Paper›PMID 40241569›Full record

ArticleESC heart failure2025

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge-to-edge mitral valve repair.

Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji and 21 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Ai KagaseDepartment of Cardiology, Nagoya Heart Center, Nagoya, Japan.
Masanori YamamotoDepartment of Cardiology, Nagoya Heart Center, Nagoya, Japan.
Takahiro TokudaDepartment of Cardiology, Nagoya Heart Center, Nagoya, Japan.
Ryotaku KawahataDepartment of Cardiology, Nagoya Heart Center, Nagoya, Japan.
Hiroto NishioDepartment of Cardiology, Nagoya Heart Center, Nagoya, Japan.
Tetsuro ShimuraDepartment of Cardiology, Gifu Heart Center, Gifu, Japan.
Ryo YamaguchiDepartment of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.
Mitsuru SagoDepartment of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.
Yuki IzumiDepartment of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
Mike SajiDepartment of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
Masahiko AsamiDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Yusuke EntaDepartment of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
Masaki NakashimaDepartment of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
Shinichi ShiraiDivision of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Masaki IzumoDivision of Cardiology, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.
Shingo MizunoDepartment of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan.
Yusuke WatanabeDepartment of Cardiology, School of Medicine, Teikyo University, Tokyo, Japan.
Makoto AmakiDepartment of Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Kazuhisa KodamaDivision of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Junichi YamaguchiDepartment of Cardiology, Tokyo Woman's Medical University, Tokyo, Japan.
Toru NaganumaDepartment of Cardiology, New Tokyo Hospital, Chiba, Japan.
Hiroki BoutaDepartment of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
Yohei OhnoDepartment of Cardiology, Tokai University School of Medicine, Isehara, Japan.
Masahiro YamawakiDepartment of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan.
Hiroshi UenoSecond Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kazuki MizutaniDivision of Cardiology, Department of Medicine, Faculty of Medicine, Kinki University, Osaka, Japan.
Daisuke HachinoheDepartment of Cardiology, Sapporo Cardiovascular Clinic, Sapporo, Japan.
Toshiaki OtsukaDepartment of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
Shunsuke KuboDepartment of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
Kentaro HayashidaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
OCEAN‐Mitral Investigators

Funding

Abbott MedicalBoston ScientificDaiichi-Sankyo CompanyEdwards LifesciencesMedtronic
6 · The paper itself

Abstract

aimsPlasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge-to-edge mitral valve repair (M-TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients. METHODS AND

resultsData from 3763 patients who underwent M-TEER were analysed from a Japanese multicentre registry. Patients were classified into functional MR (FMR) and degenerative MR (DMR) according to MR aetiology, and the median PVS values for each were calculated (FMR 12.7, DMR 14.4). The median value was used as the cut-off, stratifying the cohort into a high PVS group (n = 1882) and a low PVS group (n = 1881). All-cause mortality, cardiovascular death, and heart failure (HF) hospitalization between these two groups were compared up to 3 years in the overall, FMR, and DMR populations. The cumulative incidence rates of all-cause mortality, cardiovascular death, and HF hospitalization were higher in the high PVS group than in the low PVS group (47.0% vs. 22.2%, P < 0.001, 31.6% vs. 13.6%, P < 0.001, and 35.9% vs. 24.7%, P < 0.001, respectively). Similar trends in terms of all-cause mortality, cardiovascular death, and HF hospitalization were observed in the FMR and DMR cohorts (all P < 0.05). In the multivariate Cox regression analysis, the high PVS compared with the low PVS group was independently associated with the increased risk of all-cause death (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.01-1.03; P < 0.001), cardiovascular death (HR, 1.02; 95% CI, 1.01-1.03, P < 0.001) and HF hospitalization (HR, 1.02; 95% CI, 1.01-1.02, P < 0.001). An independent association between a high PVS and all-cause death, cardiovascular death, and HF hospitalization was also found in FMR and DMR sub-groups (all P < 0.05) while reducing MR severity to moderate or less after M-TEER was associated with improved outcomes in both the high and low PVS groups.

conclusionsPreoperative PVS is a strong independent prognostic marker in patients undergoing M-TEER, correlating with increased risk of mortality and HF hospitalization. PVS may provide valuable clinical insights for patient stratification and management strategies in M-TEER patients.

Indexed as

Cardiac CatheterizationHeart Valve Prosthesis ImplantationMitral ValveMitral Valve InsufficiencyPlasma VolumeRegistriesAgedAged, 80 and overEchocardiography, TransesophagealFemaleFollow-Up StudiesHumansJapanMalePrognosisRetrospective StudiesHeart failureMitral regurgitationPlasma volume statusTranscatheter edge‐to‐edge mitral valve repair

Identifiers

PMID40241569
PMCPMC12287850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.